Vmbook Online ordering
Cra International Inc
Sure, here's some general information about Cara Therapeutics, Inc. (CARA), a publicly-traded company listed on the NASDAQ stock exchange under the ticker symbol "CARA":
1. Company Overview: Cara Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative therapeutics to treat pain and pruritus (itching). The company's mission is to develop therapies that will improve the lives of patients suffering from these conditions.
2. Product Pipeline: Cara's product pipeline includes several drug candidates, including:
a. KORSUVA (CR845): This drug is a peripherally acting kappa opioid receptor agonist that is being developed for the treatment of pruritus associated with chronic kidney disease (CKD) and atopic dermatitis. KORSUVA has been granted Fast Track status by the FDA.
b. CR7343: This drug is a difelikefalin injection that is being developed for the treatment of moderate-to-severe chronic pain.
c. CR845-202: This drug is a Phase II-ready, selective kappa opioid receptor agonist that is being developed for the treatment of moderate-to-severe pain.
d. CR7343-202: This drug is a Phase II-ready, selective kappa opioid receptor agonist that is being developed for the treatment of moderate-to-severe pain.
3. Clinical Trials: Cara Therapeutics is currently conducting several clinical trials for its drug candidates, including:
a. KORSUVA-OK: This is a Phase 3 clinical trial evaluating the safety and efficacy of KORSUVA (CR845) for the treatment of pruritus associated with CKD.
b. KORSUVA-AD: This is a Phase 2 clinical trial evaluating the safety and efficacy of KORSUVA (CR845) for the treatment of pruritus associated with atopic dermatitis.
c. CR7343-202: This is a Phase 1 clinical trial evaluating the safety and efficacy of CR7343 for the treatment of moderate-to-severe chronic pain.
4. Financial Performance: Cara Therapeutics' stock price has been volatile in recent months due to the ongoing clinical trials and regulatory developments. As of March 2023, the company's market capitalization is around $1.4 billion.
5. Management Team: The company's management team has extensive experience in the biotechnology and pharmaceutical industries, with expertise in drug development, regulatory affairs, and commercialization. The team is led by Chief Executive Officer, Derek Chalmers, Ph.D.
6. Recent Developments: In February 2023, Cara Therapeutics announced positive top-line results from its Phase 3 KORSUVA-OK trial for the treatment of pruritus associated with CKD. The company plans to submit a New Drug Application (NDA) to the FDA for KORSUVA in the second half of 2023.
Overall, Cara Therapeutics is a biotechnology company focused on developing innovative therapies for pain and pruritus management. The company's recent positive clinical trial results and regulatory progress have generated excitement in the investment community, and the company's stock price has reacted accordingly. However, investing in biotech companies can be risky, and investors should thoroughly research the company's financials, clinical trials, and regulatory landscape before making any investment decisions.